UCB and Veeva Announce Collaboration
Veeva Systems has announced a collaboration with UCB, whereby the pharma company will adopt Veeva's ePRO and eConsent solutions, to provide a patient-centric, digital experience to study participants.
Veeva ePRO offers the design, management, and completion of electronic patient-reported outcomes (ePRO) with data flow among sponsors, sites, and patients. Veeva eConsent offers the set-up, completion, and review of consent for patients, sites, and study teams. Both applications are available to patients through MyVeeva for Patients, which provides access for participants clinical trial activities, scheduling, and communications. Veeva ePRO and Veeva eConsent are part of Veeva Vault Clinical Suite, a set of integrated capabilities for both clinical operations and clinical data management.
Reference
UCB and Veeva Collaborate to Advance the Patient Experience in Clinical Trials. (May 23, 2023). Cision PR Newswire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
